WO2002013847A3 - Methods for diagnosis and therapy of hematological and virus-associated malignancies - Google Patents

Methods for diagnosis and therapy of hematological and virus-associated malignancies Download PDF

Info

Publication number
WO2002013847A3
WO2002013847A3 PCT/US2001/025408 US0125408W WO0213847A3 WO 2002013847 A3 WO2002013847 A3 WO 2002013847A3 US 0125408 W US0125408 W US 0125408W WO 0213847 A3 WO0213847 A3 WO 0213847A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
virus
methods
hematological
diagnosis
therapy
Prior art date
Application number
PCT/US2001/025408
Other languages
French (fr)
Other versions
WO2002013847A2 (en )
Inventor
Alexander Gaiger
Martin A Cheever
Susan Hand-Zimmermann
Original Assignee
Corixa Corp
Alexander Gaiger
Martin A Cheever
Susan Hand-Zimmermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Abstract

The present invention is directed to methods for detecting and treating hematological and virus-associated malignancies using Her2/neu sequences. The Her2/neu sequences may be polypeptides or polynucleotides.
PCT/US2001/025408 2000-08-14 2001-08-13 Methods for diagnosis and therapy of hematological and virus-associated malignancies WO2002013847A3 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US63828000 true 2000-08-14 2000-08-14
US09/638,280 2000-08-14
US67590400 true 2000-09-28 2000-09-28
US09/675,904 2000-09-28

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU8336001A AU8336001A (en) 2000-08-14 2001-08-13 Methods for diagnosis and therapy of hematological and virus-associated malignancies

Publications (2)

Publication Number Publication Date
WO2002013847A2 true WO2002013847A2 (en) 2002-02-21
WO2002013847A3 true true WO2002013847A3 (en) 2002-12-19

Family

ID=27093044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025408 WO2002013847A3 (en) 2000-08-14 2001-08-13 Methods for diagnosis and therapy of hematological and virus-associated malignancies

Country Status (1)

Country Link
WO (1) WO2002013847A3 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1583833A1 (en) 2003-01-03 2005-10-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Rhesus her2/neu, nucleotides encoding same, and uses thereof
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
CN107335062A (en) 2010-06-08 2017-11-10 基因泰克公司 Cysteine engineered antibodies and conjugates
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Conjugates of the antibody and alaninyl-maytansinol
RU2638806C2 (en) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms method for multiple reactions monitoring to identify therapeutic antibodies in animal species using framework signature peptides
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
JP5993093B2 (en) 2012-10-12 2016-09-14 メドイミューン・リミテッドMedImmune Limited Pyrrolo benzodiazepines and their complexes
KR20150085814A (en) 2012-10-12 2015-07-24 에이디씨 테라퓨틱스 에스에이알엘 Pyrrolobenzodiazepine-antibody conjugates
CN105050661B (en) 2012-10-12 2018-03-30 Adc疗法责任有限公司 Pyrrolo benzodiazepine - antibody conjugate
KR20150131203A (en) 2013-03-13 2015-11-24 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
CN105209077A (en) 2013-03-13 2015-12-30 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
CA2918139A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
CN107106700A (en) 2013-12-16 2017-08-29 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (en) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド Cysteine ​​engineered antibodies and conjugates
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
US10058613B2 (en) 2015-10-02 2018-08-28 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3362100A1 (en) 2015-10-16 2018-08-22 Genentech, Inc. Hindered disulfide drug conjugates
WO2017068511A1 (en) 2015-10-20 2017-04-27 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 Multiplexing total antibody and conjugated drug antibody assay quantization
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US20170348422A1 (en) 2016-06-06 2017-12-07 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711565A1 (en) * 1994-11-10 1996-05-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibiting growth of leukemic cells by targeting HER-2 protein
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO2001021192A2 (en) * 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0711565A1 (en) * 1994-11-10 1996-05-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibiting growth of leukemic cells by targeting HER-2 protein
WO2001021192A2 (en) * 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROSSART PETER ET AL: "Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 96, no. 9, 1 November 2000 (2000-11-01), pages 3102 - 3108, XP002172006, ISSN: 0006-4971 *
BUHRING H-J ET AL: "THE RECEPTOR TYROSINE KINASE P185 HER2 IS EXPRESSED ON A SUBSET OF B-LYMPHOID BLASTS FROM PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND CHRONIC MYELOGENOUS LEUKEMIA", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 86, no. 5, 1 September 1995 (1995-09-01), pages 1916 - 1923, XP000560897, ISSN: 0006-4971 *
DISIS M L ET AL: "Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 156, no. 9, 1 May 1996 (1996-05-01), pages 3151 - 3158, XP002139506, ISSN: 0022-1767 *
GALY A ET AL: "Generation of immunogenic dendritic cells that are gene-modified to present the ERBB2 antigen.", IMMUNOLOGY, vol. 92, no. SUPPL. 1, December 1997 (1997-12-01), 5th Annual Congress of the British Society for Immunology;Brighton, England, UK; December 2-5, 1997, pages 12, XP001074064, ISSN: 0019-2805 *
IMAMURA N ET AL: "AGGRESSIVE DIFFUSE LYMPHOMA COEXPRESSING NRAS P21 AND C-ERBB-2 (NEU) ONCOGENE PRODUCTS, AND CALLA (CD10)", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 4, no. 5/6, 1991, pages 419 - 422, XP000560889, ISSN: 1042-8194 *
TIMMERMAN J M ET AL: "DENDRITIC CELL VACCINES FOR CANCER IMMUNOTHERAPY", ANNUAL REVIEW OF MEDICINE: SELECTED TOPICS IN THE CLINICAL SCIENCES, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 50, 1999, pages 507 - 529, XP001005422, ISSN: 0066-4219 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Also Published As

Publication number Publication date Type
WO2002013847A2 (en) 2002-02-21 application

Similar Documents

Publication Publication Date Title
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2003057134A3 (en) Specific binding agents of human angiopoietin-2
GB2370115B (en) Method of treating biological specimens
WO2002016429A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP